This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2025-07-14), Guardant Health's share price is $50.25. Guardant Health's Median PS Value is $0.00. Therefore, Guardant Health's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Guardant Health's Median PS Value or its related term are showing as below:
GH's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.87 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Guardant Health Median PS Value Historical Data
The historical data trend for Guardant Health's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Guardant Health's Median PS Value
For the Diagnostics & Research subindustry, Guardant Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's Price-to-Median-PS-Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Guardant Health's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.277.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Guardant Health's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
50.25
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health Median PS Value Related Terms
Thank you for viewing the detailed overview of Guardant Health's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 